Skip to main content
Premium Trial:

Request an Annual Quote

Norman Russell and Al Kolb


Invitrogen last week said that Norman Russell has joined the company as vice president and general manager of the functional genomics strategic business unit.

In this role, Invitrogen said, Russell will lead the company’s genomics, proteomics, and RNAi product lines. He joins Invitrogen from Aviva Biosciences, where he served as president and CEO. Prior to that, Russell was president and CEO of Lynx Therapeutics. He also served for many years for AstraZeneca, Invitrogen said. Russell holds a PhD in physiology from Glasgow University.

Al Kolb is currently serving as the 2004-2005 president elect for the Society for Biomolecular Screening, the organization announced last week. He will assume the presidency at the society’s 11th Annual Conference and Exhibition to be held Sept. 11-15 in Geneva.

Kolb is a consultant for KeyTechnology Consulting in Madison, Conn. He was one of the founding members of the society, SBS said, and a member of the first board of directors in 1994, and from 1999 through 2000. He has also served as a member of the editorial board of the Journal of Biomolecular Screening since its inception. Kolb holds a PhD in molecular biology from the University of California, Irvine, and completed a postdoctoral fellowship at the Roche Institute for Molecular Biology.


The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.